RESEARCH AGREEMENT (Non-Clinical)

Exhibit 10.30

RESEARCH AGREEMENT

(Non-Clinical)

This Agreement (“Agreement”) entered into this 1st day of July, 2022 (“Effective Date”), by and between the University of Miami, (“University”) and Jupiter Neurosciences, Inc. (“Company”) to conduct a study entitled: EVALUATION of JOTROL in ▇▇▇▇▇▇▇▇▇’▇ DISEASE MODELS (“Study”) as described in the protocol/scope of work attached hereto as Exhibit A and made a part hereof.

1. Principal Investigator.

The Principal Investigator(s) for University shall be ▇▇▇▇▇ ▇▇▇▇▇▇▇▇. The Technical Director(s) for Company shall be ▇▇▇▇▇▇ ▇. ▇▇▇▇▇.

2. Amount of Funding.

The amount of the funding for the conduct of the Study is $72,844.00 (Exhibit B). One-Hundred percent (100%) of this amount will be paid by Company to University. $24,000 to be paid upon execution of this Agreement, $24,000 upon first dosing of JOTROL in the animals and the remaining amount, $24,844 upon completion of final study result report. Amendments to the original agreement must be paid in full (100%) upon execution.

	All payments shall be paid to the
	University of Miami (Tax I.D. # ▇▇-▇▇▇▇▇▇▇)
	and sent to:
	Office of Research Administration
	▇▇ ▇▇▇ ▇▇▇▇▇▇
	▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇
	Also mail a copy to:	▇▇▇▇▇ ▇▇▇▇▇▇▇▇
		▇▇▇▇ ▇▇ ▇▇▇▇ ▇▇▇, ▇▇▇▇ ▇▇▇
		▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇

It is expected that grant funds will be expended in general accordance with the budget attached. Actual expenditures may vary at the discretion of University. Upon completion of the Study, any unexpended funds will be retained by University.

3. Reporting Requirements (if any).

A study report will be sent to the Company after completion and receipt of the final payment.

4. Term of Agreement.

Performance of this Agreement shall begin upon the Effective Date and shall continue for a period of one (1) year unless earlier terminated pursuant to this Agreement. Either Company or University may terminate this Agreement upon thirty (30) days written notice for any reason.

In the event of such termination, both Company and the University shall take all reasonable steps to cancel further costs in connection with this agreement. Company and University will be entitled to reimbursement for costs and non-cancelable obligations incurred prior to effective day of the termination, except in no event shall such reimbursement exceed the total amount stipulated in Section 2.

5. Confidential Information.

The parties may disclose to each other certain confidential and proprietary information and materials relating to the Study, or other proprietary information of a technical, business or other nature for the purpose of facilitating, supporting and/or conducting the Study. All confidential and proprietary information exchanged by the parties shall constitute “Confidential Information.”

Each party agrees that, for a period of five (5) years following the termination or expiration of this Agreement, it shall retain in confidence the Confidential Information of the other party, and will prevent disclosure of such Confidential Information to third parties. Such restriction shall not apply to Confidential Information which:

	a)	was available to the general public or otherwise part of the public domain prior to or at the time of disclosure to the receiving party;
	b)	became generally available to the public or otherwise part of the public domain after its disclosure to the receiving party other than through an act or omission of the receiving party;
	c)	was already properly known to the receiving party at the time of disclosure to the receiving party as evidenced by prior written records of the receiving party;
	d)	was properly disclosed to the receiving party, other than under an obligation of confidentiality, by a third party who had no obligation of confidentiality to the disclosing party not to disclose such information to others;
	e)	was published pursuant to Section 6 of this Agreement; or
	f)	was independently developed by employees of the receiving party without reference to the disclosing party’s Confidential Information.

6. Publication Rights.

University shall have publication privileges in reference to the Study. Company agrees that the Principal Investigator for the University shall be permitted to publish in journals, theses, dissertations, or other formats of their own choosing, and to present at symposia and national or regional professional meetings, the methods and results of the Study, subject to the following. At least thirty (30) days in advance of the submission of such proposed publication or presentation to a journal, editor, or other third party, University shall furnish Company copies of the proposed publication, abstract, theses, dissertations or presentation. The purposes for such prior submission are: (i) to provide Company with the opportunity to review and comment on the contents of the proposed publication or presentation; (ii) to identify any Confidential Information to be deleted from the proposed publication or presentation (excluding Study data and results); and (iii) to allow time for any patentable subject matter to be identified. Company shall provide any comments to University within thirty (30) days of receipt of the proposed publication or presentation. University shall give due consideration to any comments made by Company however, University shall have no obligation to incorporate Company’s comments into the publication. University hereby agrees to delete from the proposed publication any Confidential Information which Company requests University to delete but only to the extent such deletion does not preclude the complete and accurate presentation and interpretation of the Study results. Company shall have thirty (30) days after receipt of the proposed publication or presentation to object to the proposed publication or presentation on the grounds that there is patentable subject matter that needs protection. In the event Company makes such objection, the University shall refrain from making such publication or presentation for no longer than sixty (60) days from the date of receipt of such objection (unless extended by written agreement of the Parties) in order for patent application(s) directed to the patentable subject matter contained in the proposed publication or presentation to be filed.

2

In any publication in connection with the Study, University shall acknowledge the contributions of Company as scientifically appropriate.

University shall furnish all data resulting from this Study to the Company.

7. Intellectual Property.

Ownership of inventions, discoveries, works of authorship and other developments existing as of the Effective Date hereof, and all patents, copyrights, Confidential Information, trade secret rights and other intellectual property rights therein (collectively, “Pre-existing Intellectual Property”), is not affected by this Agreement, and neither party shall have any claims to or rights in any Pre-existing Intellectual Property of the other party, except as may be otherwise expressly provided in any other written agreement between them.

Title to any inventions or discoveries conceived or reduced to practice by Company pursuant to conducting the Study shall belong to Company (“Company Inventions”). Title to any inventions or discoveries conceived or reduced to practice by University that are related to or arise out of the Study or any improvements made by University upon materials provided by Company for the conduct of the Study shall be owned jointly by both Company and the University (“Joint Inventions”). Title to any other inventions or discoveries conceived or reduced to practice by University pursuant to conducting the Study shall belong to University (“University Inventions). University shall retain, at all times, a non-exclusive worldwide royalty free license to use Company Inventions and Company’s interest in Joint Inventions to perform the Study, for its internal educational, non-commercial research, and patient care purposes, and to comply with any applicable laws and regulations.

8. Indemnification.

Each party shall be solely responsible for the payment of any and all claims for loss, personal injury, death, property damage, or otherwise arising out of any act or omission of its employees or agents in connection with the performance of its obligations under this Agreement. Each party agrees to indemnify and hold the other party harmless from any and all claims, loss, damages, costs, expenses, actions, lawsuits and judgments thereon including attorneys’ and experts’ fees and costs through the appellate levels (the “Indemnifying Party”) made against or incurred by the other party (the “Indemnified Party”) arising out of or relating to any act or omission of the Indemnifying Party, its agents and employees.

3

The provisions of this paragraph and paragraph 8 shall continue after the termination of this Agreement.

9. Insurance.

Company agrees to carry and keep in force, at its expense, general liability insurance with limits not less than $1,000,000 per occurrence and $2,000,000 aggregate to cover liability for damages on account of bodily or personal injury or death to any person, or damage to property.

Prior to execution of this Agreement, Company shall provide a certificate of insurance or a self-insurance letter (if Company is self-insured) stating the limits of coverage.

10. University Employees

Unless otherwise approved in writing by University, only University employees shall participate in any professional and technical activities of this Study. Company agrees to release, hold harmless and indemnify University from and against any and all losses, claims, or damages, including bodily injury or death or property damage, and including attorney fees through the appellate level, suffered by Company, and its agents and employees while on University premises, or arising out of or relating to any act or omission of Company, its agents and employees, provided that such loss, claim or damage does not arise out of negligence of University.

11. Use of Name.

Company agrees that it will not under any circumstances use the name of University or any faculty or employee in advertising, press release, publicity, or other public announcement, written or verbal, whether to the public press or otherwise, without the express written permission of University Assistant Vice President for Business Services, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇. University shall acknowledge Company’s support of the research program under this Agreement in scientific publications and other scientific communications.

12. Materials.

All equipment and materials acquired for use in connection with the Study will be the property of University at the termination of the Agreement. Except as may be otherwise provided in this Agreement, title to any equipment provided by Company to University shall pass to University at the time of delivery thereof to University. Any assays, sequences, clones, mutants, or technologies not directly related to the Company’s technology, developed or discovered by the investigators shall be the property of the investigators in accordance with University of Miami policies.

4

13. WARRANTIES.

UNIVERSITY MAKES NO WARRANTIES, EXPRESS OR IMPLIED AND HEREBY DISCLAIMS ALL SUCH WARRANTIES, AS TO ANY MATTER WHATSOEVER INCLUDING, WITHOUT LIMITATION, THE CONDITION OF THE RESEARCH OR ANY INVENTION(S) OR PRODUCT(S), WHETHER TANGIBLE OR INTANGIBLE, CONCEIVED, DISCOVERED, OR DEVELOPED UNDER THIS AGREEMENT; OR THE OWNERSHIP, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE RESEARCH OR ANY SUCH INVENTION OR PRODUCT. UNIVERSITY SHALL NOT BE LIABLE FOR ANY DIRECT, CONSEQUENTIAL, OR OTHER DAMAGES SUFFERED BY ANY LICENSEE OR ANY THIRD PARTIES RESULTING FROM THE USE OF THE RESEARCH OR ANY SUCH INVENTION OR PRODUCT.

The provisions of this paragraph shall continue beyond the termination of this Agreement.

14. Federal Regulations.

No human subject testing shall be conducted under this Agreement. Any studies involving the use of vertebrate animals shall comply with all state and federal statutes, rules and regulations governing animal care and use. Any studies involving isotopes must comply with any and all applicable state and federal rules, regulations and statutes. Recombinant DNA research shall be performed in accordance with regulations promulgated as Guidelines for Research Involving Recombinant DNA Molecules, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health.

15. Conflicts.

In the event there is a conflict with the terms of this Agreement, the protocol/scope of work or any other documents pertaining to this Study, the terms of this Agreement shall govern.

16. Governing Law.

This Agreement shall be governed by the laws of the State of Florida.

17. Notices.

All notices which either party is required to give to the other in conjunction with this Agreement shall be in writing, and shall be given by certified mail, return receipt requested, or by delivering the same personally, or by courier or Federal Express (or comparable overnight courier) to such other party, or by facsimile (with confirmation by any other method accepted herein). Any notice given by certified mail shall be deemed to have been received three (3) days following the date of mailing. If hand delivered or delivered by same day or overnight courier or by facsimile, such notice shall be deemed to have been received on the date of delivery to the party being noticed. All notices shall be sent to the addresses specified below:

University of Miami Attn: Exec. Director, Office of Research Administration ▇▇▇▇ ▇. ▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇, #▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇ Email: ▇▇▇▇@▇▇▇.▇▇▇▇▇.▇▇▇ cc: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇ ▇▇▇▇ ▇▇▇ ▇▇▇▇ ▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇ Email: ▇▇▇▇▇▇▇▇▇@▇▇▇.▇▇▇▇▇.▇▇▇ Jupiter Neurosciences, Inc. Attn: ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇ ▇ ▇▇ ▇▇▇ ▇, ▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ Email: ▇.▇▇▇▇▇@▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ cc: ▇▇▇▇▇▇ ▇▇▇▇▇ Email: ▇.▇▇▇▇▇@▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ cc: ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ Email: ▇.▇▇▇▇▇▇▇@▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇

18. Entire Agreement.

There are no oral agreements with respect to the subject matter of this Agreement which are not fully expressed herein. No representations, understanding, or agreements have been made or relied upon in the making of this Agreement other than those specifically set forth herein. This Agreement can only be modified by a writing signed by duly authorized representatives of both parties.

[Remainder of page left intentionally blank]

5

IN WITNESS THEREOF, the parties have executed this agreement by their duly authorized officers on the date first herein set out:

UNIVERSITY OF MIAMI:		COMPANY:
/s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, JD		/s/ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
Authorized Organizational Representative		Authorized Company Representative
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, JD,		▇▇▇▇▇▇▇▇ ▇▇▇▇▇
Exec. Director, Office of Research Admin		Chairman and CEO
Name and Title		Name and Title
June 21, 2022		June 21, 2022
Date		Date

6

EXHIBIT A

Protocol/Scope of Work

Center for Therapeutic Innovation, University of Miami ▇▇▇▇▇▇ School of Medicine

EVALUATION of JOTROL

in ▇▇▇▇▇▇▇▇▇’▇ DISEASE MODELS

▇▇▇▇▇ ▇▇▇▇▇▇▇▇, PhD, MBA

▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, PhD

Confidential 1

Center for Therapeutic Innovation, University of Miami ▇▇▇▇▇▇ School of Medicine

PROPOSAL OVERVIEW

The investigations proposed here aim to first, validate JOTROL as a preclinical candidate for the treatment of ▇▇▇▇▇▇▇▇▇’▇ disease (PD). Second, to determine that this drug represents the best possible candidate as compared to currently available treatment options. To validate other candidates in the same drug series, such as unformulated resveratrol and piceatannol for response and efficacy. To begin to work out the mechanism of action for this compound to alleviate motor dysfunction. To validate the mechanism of this drug in animals and animal models of PD. To determine whether the high blood concentrations of JOTROL will be meaningfully achieved and how this translates to its therapeutic efficacy in this disease state, similarly to its potential clinical relevance for other neurological diseases as Alzheimer’s disease and MPSI. Finally, we aim to begin the data gathering process that is necessary to enable human experimentation and clinical trials. Particularly for this, the experimental approach was modeled on the identical ways in which current clinical candidates for PD were validated for having human therapeutic potential.

PROJECT GOAL

Overall Goal: Evaluate JOTROL activity in a classic toxin model of ▇▇▇▇▇▇▇▇▇’▇ disease in mice.

Objective 1: Validate the protective capacity of JOTROL in a unilateral intracranial MPTP model using motor behavioral testing.

● The neuroprotective capacity of JOTROL will be evaluated on general health and motor behaviors of animals unilaterally microinfused with MPTP. Well validated PD behavioral tests will be utilized following the infusion of either vehicle or toxin, including open-field, grip strength, rotarod, L-DOPA responsivity and methamphetamine-induced rotations, while also monitoring the animals’ weights throughout the duration of the study.

Objective 2: Validate protective capacity of JOTROL on dopaminergic neurons in the SN and dopamine content in the striatum.

● The neuroprotective actions of JOTROL will be determined by assessing altered tyrosine hydroxylase (TH) activity in the SN, TH, dopamine transporter (DAT), dopamine and GABA content in the striatum and other analyses of basal ganglia neuronal populations involved in PD and motor function. This will be conducted in the unilateral MPTP model of PD and control animals that were treated with JOTROL.

Confidential 2

Center for Therapeutic Innovation, University of Miami ▇▇▇▇▇▇ School of Medicine

PROPOSED PROJECT SCHEDULE

TIMELINE		PROPOSED TREATMENT		PROPOSED WORK
				Baseline Behavior
WEEK 1		None		Weights Open-Field Test
				Grip Strength
				Rotarod
				Stereotaxic Surgery
		Unilateral Infusion with either Vehicle or MPTP into the SN and MFB (50 µg)		C57/BL6 Mice (30+ grams), N=8/group (Total: 40 mice) 5 Groups:
WEEK 2		Daily oral gavage of Vehicle or JOTROL starting same day of surgery (first dose immediately after surgery completion)		Sham-infused, Vehicle-treated Sham-infused, JOTROL-treated MPTP-infused, Vehicle-treated  MPTP-infused, JOTROL-treated (Low Dose: 25 mg/kg) MPTP-infused, JOTROL-treated (High Dose: 50 mg/kg)
WEEK 3		Daily oral gavage of Vehicle or JOTROL		Recovery Week – remove wound clips 7-10 days post-op Weights
WEEK 4		Daily oral gavage of Vehicle or JOTROL		Weights Open-Field Test Grip Strength Rotarod
WEEK 5		Daily oral gavage of Vehicle or JOTROL		Weights Open-Field Test Grip Strength Rotarod
WEEK 6		Daily oral gavage of Vehicle or JOTROL		Weights Open-Field Test Grip Strength Rotarod
Week 7		Daily oral gavage of Vehicle or JOTROL		Weights Open-Field Test Grip Strength Rotarod
Week 8		Daily oral gavage of Vehicle or JOTROL		Weights L-DOPA Responsivity: Grip Strength & Rotarod
Week 9		Daily oral gavage of Vehicle or JOTROL  Methamphetamine, i.p. (5 mg/kg)		Weights Methamphetamine-induced Rotations
Week 10		Daily oral gavage of Vehicle or JOTROL		Weights Open-Field Test Grip Strength Rotarod
Week 11		Daily oral gavage of Vehicle or JOTROL		Transcardial Perfusions or Fresh Tissue Collection
Week 12+		N/A		Western Blot & HPLC Analysis of Brain Samples

Confidential 3

Center for Therapeutic Innovation, University of Miami ▇▇▇▇▇▇ School of Medicine

BACKGROUND

▇▇▇▇▇▇▇▇▇’▇ disease (PD), the second most common age-related neurodegenerative disorder after Alzheimer’s disease^1,2, is characterized by the loss of dopamine-producing neurons within the substantia nigra pars compacta (SN) of the direct motor pathway, which in turn contributes to postsynaptic dopamine depletion within the striatum. This loss of dopamine functionality results in motor behavioral deficits including uncontrollable tremor, postural imbalance, rigidity and slowness of movement³. The severity of motor symptoms is due to the loss of tyrosine hydroxylase (TH)-positive dopaminergic neurons in the SN⁴. Presently, PD therapeutic options available only address symptoms and primarily include dopamine replacement therapy with levodopa (L-DOPA)^5–9. L-DOPA was approved for the treatment of PD in the late 1960s and is the most widely used prescription drug for PD^10,11. Since L-DOPA/carbidopa therapy only helps to control motor symptoms of PD and does not prevent or slow disorder progression, it is important to advance understanding of idiopathic PD onset and progression.

The specific etiology of PD remains unknown although there are genetic and environmental factors linked to disease development. Several causative monogenetic mutations have been identified^12–14. However, only a small percentage of cases (~10%) are the result of inheritable genetic mutations¹. The remaining cases (~90%) are sporadic or idiopathic in origin, although evidence suggests that exogenous toxins such as cyanide, trace metals, organic solvents and exposure to pesticides increase the risk of developing PD^15–19. Epidemiological studies have demonstrated a strong link between environmental pesticide exposure with increased incidence of PD in humans^20–26. Indeed, idiopathic PD and the underlying epigenetic changes, have long been modeled using neurotoxins, including 6- hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which all target dopaminergic neurons and lead to a parkinsonian syndrome.

Several animal models exist that produce irreversible behavioral and molecular effects, such as those observed with this disease. The most extensively studied animal model of PD uses 6-hydroxydopamine (6-OHDA). 6-OHDA is a hydroxylated analogue of the naturally occurring neurotransmitter, dopamine, with a high affinity for the dopamine transporter and was the first model used to study PD ²⁷. 6-OHDA is unable to cross the blood-brain barrier so local injection is required in order to obtain the desired effects^28,29. When 6-OHDA is injected into the substantia nigra (SN) or medial forebrain bundle (MFB), it selectively accumulates in dopamine neurons resulting in anterograde degeneration and cell death³⁰. When 6-OHDA is infused into the striatum retrograde degeneration of the nigrostriatal pathway also occurs causing a substantial loss of striatal dopamine and SN dopaminergic neurons^31,32. Unilateral infusions with 6-OHDA also produce considerable motor deficits as a result of dopamine depletion, the extent of which can be assessed by evaluating rotational behavior following administration of either amphetamine or apomorphine^28,33. Unfortunately, 6-OHDA does not induce all pathological features of PD, as α-synucleinopathy and the formation of Lewy bodies do not occur^27,34.

The link between mitochondria and ▇▇▇▇▇▇▇▇▇’▇ disease was first postulated in 1979 after a college student had attempted to synthesize the heroin analog 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), but accidentally contaminated the drug with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), such that when he self-administered the drug, he began to suffer from Parkinsonism-like symptoms ²⁵. This effect was observed again in 1982 when a young group of illicit drug users developed very progressive parkinsonian symptoms following intravenous administration of MPPP that was contaminated with MPTP ^1,35. Research revealed that MPTP can easily cross the blood-brain barrier where it is oxidized into 1-methyl-4-phenylpyridinium (MPP+) by the enzyme monoamine oxidase B ³⁶. Due to its similarity in structure to dopamine, MPP+ is taken up by the dopamine transporter, leading to inhibition of complex I (nicotinamide adenine dinucleotide (NADH)-ubiquinone oxireductase) activity of the electron transport chain and, ultimately, cell death ^30,37. Furthermore, animal studies revealed that

Confidential 4

Center for Therapeutic Innovation, University of Miami ▇▇▇▇▇▇ School of Medicine

MPTP and other inhibitors of mitochondrial function, such as the pesticide rotenone, produce many of the same characteristics observed in ▇▇▇▇▇▇▇▇▇’▇ disease including behavioral deficits, nigrostriatal degeneration, and protein aggregation ^38–45.

MPTP can cross the blood-brain barrier due to its high lipophilicity, where it is oxidized in glial cells and serotonergic neurons to 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+), catalyzed by monoamine oxidase B ⁴⁶. MPDP+ is very unstable and spontaneously oxidizes to MPP+. MPP+ is then released into the extracellular space and taken up via the dopamine transporter, where it targets mitochondria and inhibits complex I activity of the electron transport chain. This leads to a decrease in the production of adenosine triphosphate (ATP), while increasing the generation of reactive oxygen species, resulting in neuronal cell death ^27,30. MPTP is one of the most commonly used animal models for this disorder, as administration of this toxin results in motor symptoms and dopaminergic deterioration along the nigrostriatal pathway that are very similar to that observed in ▇▇▇▇▇▇▇▇▇’▇ disease ⁴⁷. The shortcomings associated with this technique include an inconsistency in the loss of other monoaminergic neurons, such as those located in the locus coeruleus, and a lack of Lewy body formation ³⁴.

Due to the current level of understanding of the disease, diagnosis of patients with PD only occurs once individuals exhibit dysfunctional motor symptoms, indicating that those suffering from the disorder have already lost at least 50% of their dopaminergic neuron population in the SN and up to or exceeding 80% of the dopaminergic content in their striatum⁴⁸. Therefore, preventative therapies or strategies for preventing the onset or slowing the rate of progression are necessary for the treatment of PD, however such interventions are not currently available. As mentioned previously, the therapeutic options currently available only address either motor or non-motor symptom management, and primarily include the use of the hallmark dopamine replacement therapy, levodopa (L-DOPA). L-DOPA was approved for the treatment of PD in the late 1960s and is the most widely used prescription drug for PD^10,11. L-DOPA is absorbed by the intestines, crosses the blood-brain barrier, where it is converted into dopamine in the brain. It is typically combined with carbidopa or catechol-O-methyltransferase (COMT) inhibitors which prevent the breakdown of L-DOPA before it can reach the brain, prolong the duration of action of L-DOPA and limits its side effects. Treatment with L-DOPA/carbidopa or COMT inhibitors can be effective throughout the course of the disease, but due to the progressive nature of PD, increased dosages of the drug may be required over time to help control symptoms^49,50. Motor complications are very common with chronic L-DOPA treatment, with up to 50% of patients experiencing some form of motor dysfunction within 2-5 years, and between 80-100% reporting symptoms after 10 years of therapy. These motor symptoms primarily take the form of the development of dyskinesia (involuntary movements) and/or motor fluctuations, where symptoms are not controlled and can come on gradually (L-DOPA effect wears off before the next dose) or suddenly and unpredictably^51–53.

Beyond motor symptom management with the highly regarded combination L-DOPA/carbidopa, PD patients may also be prescribed other common treatments for motor impairments which include: dopamine agonists (mimic the effect of dopamine in the brain, can be used alone or in combination with other PD medications, including L-DOPA, and are less likely to lead to negative motor side effects, as compared to L-DOPA, but are also less effective for controlling motor deficits), monoamine oxidase B inhibitors (prevents the breakdown of dopamine in the brain by reducing the activity of the enzyme monoamine oxidase, can be used alone or in combination with other treatments, and offer mild symptomatic benefit in early cases of PD where the use of dopaminergic therapy is wished to be delayed or avoided), anticholinergic drugs (acetylcholine levels are increased in PD and these treatments restore the balance between this neurotransmitter and dopamine, which act to help control tremor and sometimes dystonia) and amantadine medications (act on the dopamine and glutamate neurotransmitter systems and are used to treat dyskinesia and mild PD symptoms). Another treatment option available for some patients with poorly controlled motor fluctuations is deep brain stimulation, where wires are implanted into targeted basal ganglia regions and stimulated using a remote device. The use of deep brain stimulation has shown to be effective at reducing motor symptoms and improves overall quality of life, although there are potential negative side effects associated with the procedure including speech and cognitive impairment, altered gait, and neuropsychiatric sequelae, along with surgical risks^54–60. In addition to the motor problems associated with PD, there are non-motor symptoms which can be a result of the disease itself or due to the medications used to treat the disorder. Such non-motor complications include constipation, dementia, depression or anxiety, drooling, fatigue, orthostatic hypotension, pain (directly relating to the disease, muscle pain from dystonia or bradykinesia, or injury from falls as a result from balance or walking issues), psychosis (hallucinations or delusions), sexual dysfunction, sleep disturbances, and urinary symptoms that can lead to incontinence^58,61–63. This current lack of available therapies for PD patients to slow or halt the rate of progression is disparaging and are necessary for the treatment of PD, however such interventions are not currently available, thus urging the need for better therapeutic treatment options.

Confidential 5

Center for Therapeutic Innovation, University of Miami ▇▇▇▇▇▇ School of Medicine

Several small molecule libraries were screened for protection in differentiated SH-SY5Y (dopaminergic neurons, verified using dopamine markers) treated with 6-OHDA or MPTP. Several hit compounds were found and upon validation there were several outstanding hits, but most interesting was that of resveratrol. Trans-resveratrol is a naturally occurring phytochemical found in red wine, blueberries, and many other fruits and legumes. In studies exploring clinical efficacy, it has been demonstrated that resveratrol must be administered at high doses due to its low bioavailability. In a randomized double-blind phase II clinical trial, the Alzheimer’s Disease (AD) Cooperative Study group demonstrated that administration of up to 2 grams of resveratrol per day to AD patients resulted in stabilization of Aβ40 and Aβ42 accumulation in both CSF and plasma⁶⁴. This 12-month trial began with a dosage of 500 mg daily, increasing by 500 mg every 3 months to a maximum of 1 g b.i.d. Initial dosages in this study were likely inadequate, as positive effects were obtained after only 6-12 months of resveratrol treatment; population pharmacokinetics (PK) evaluation shows that even at the highest administered dose at steady state, only about 200 ng/ml of plasma resveratrol were achieved at Cmax. Literature reports have detailed the poor bioavailability of resveratrol due to first-pass metabolism⁶⁵. To pursue this research, the investigators determined that a significantly higher bioavailability or oral resveratrol would be required to safely achieve therapeutic benefits. In the 12-month AD resveratrol study, side effects included weight loss and gastro-intestinal problems such as nausea and diarrhea that are associated with high dosage. From a pharmacodynamic viewpoint, only high dose resveratrol has achieved therapeutic benefit; importantly, some studies provide population PK data. In Friedreich’s Ataxia, a rare genetic disorder that leads to progressive nervous system degeneration and motor deficits due to mitochondrial dysfunction, positive clinical (neurological) outcomes were achieved with 5 grams (!) resveratrol/day⁶⁶. Plasma Cmax levels under 200 ng/ml did not show benefits. Further, 5 grams of resveratrol in healthy individuals gives an average peak plasma Cmax of 539±384 ng/mL, which is approximately 2.4 µmol/L, which is inadequate to elicit any beneficial biological effects as the activity of resveratrol at the biological level is observed in vitro at concentrations of 10-100 µmol/L^67–69. Importantly for our purposes, resveratrol protected dopaminergic neuronal cell death in the presence of rotenone in the in vitro assay by 3 standard deviations as compared to vehicle.

Trans-piceatannol is a derivative of resveratrol, both of which have been found to be beneficial in mucopolysaccharidosis I (MPSI), an autosomal recessive genetic disorder in which the alpha-L-iduronidase (IDUA) enzyme is greatly depleted or absent from the affected individual resulting in a buildup of the glycosaminoglycans (GAGs) heparan and dermatan sulfate GAGs. The buildup of these polysaccharide sugars in lysosomes leads to cellular disruption, inflammation, cognitive decline and others. Eventually organ failure occurs, followed by death⁷⁰. Resveratrol and piceatannol have demonstrated therapeutic potential by upregulating IDUA enzyme activity, although piceatannol has approximately 10-fold lower potency than resveratrol. While not much is known about piceatannol in humans, resveratrol has been extensively studied in humans with at least 49 clinical trials completed or ongoing in adults. No clinical trials of piceatannol have apparently been performed to date. No clinical trials of resveratrol have apparently been performed in children.

Confidential 6

Center for Therapeutic Innovation, University of Miami ▇▇▇▇▇▇ School of Medicine

Resveratrol appears to be very safe for administration to humans. Resveratrol is available over the counter from sources such as for example GNC. Available formulations for resveratrol include 500 mg capsules, 15 mg/ml DMSO injectable solutions, oral solutions and sublingual capsules, though some of these are perhaps not from trusted sources or have validated drug content. There is also apparently a transdermal patch, likely from an untrusted source, for which it is unclear what the time-lag, steady-state plasma levels, maximal exposure and dermal permeability to resveratrol are, and therefore the transdermal delivery is the least favorable for achieving high blood/brain concentrations of resveratrol. Injectable forms also appear to be quite low in initial concentration. This route is also considered suboptimal for once daily dosing. Sublingual administration clearly has benefits to circumventing first-pass liver metabolism, but it is unclear whether resveratrol passes into the bloodstream quickly enough to achieve high AUC and Cmax. Anecdotal evidence also suggests that sublingual dosing requires holding the drug under the tongue for 30 minutes or more. This could become problematic with twice or thrice daily dosing, whereupon compliance is expected to be low. Oral administration is therefore considered to be the optimal route for resveratrol administration. However, there are problems with first-pass liver metabolism reducing the overall drug residence time (AUC) and maximal concentration in the blood stream (Cmax; both are measures of how well the body takes up a drug and keeps it around, in this case the higher these are, the better). Since resveratrol demonstrates myriad of properties relevant to the treatment of PD and showed potential utility at high doses in preclinical studies, the clear problem became how to deliver resveratrol in a highly bioavailable form that is well tolerated. We evaluated several advanced drug delivery approaches to address this problem. However, transdermal or trans-buccal delivery is infeasible and the high blood levels required coupled with rapid metabolism make infusion or injection routes impractical.

Resveratrol is poorly soluble in water, and after absorption in the gut is rapidly degraded by first pass liver metabolism⁶⁵. Micronizing resveratrol prior to ingestion can improve bioavailability and adding components e.g., as emulsions or liposomes, may provide some benefits. The physio-chemical properties of resveratrol suggest absorption and bioavailability would be improved if it could be presented as a lipid like nutrient. Lipids pass into the lymph and avoid first pass liver metabolism. When resveratrol is dissolved in a lipophilic phase and is stabilized in the form of droplets in an aqueous environment in emulsions, resveratrol can be retained in a phospholipid layer in liposomes. This can increase the bioavailability as compared to the native form, but formulations of this type, such as liposomes, are extremely unstable and are not resistant to the gastric milieu.

We therefore developed a novel oral formulation of resveratrol (termed JOTROL), which shows significantly better PK properties than the current best version of resveratrol (micronized). JOTROL is a stable micellar formulation for oral administration for use as a pharmaceutical product in which the bioavailability of resveratrol is enhanced and avoids first pass metabolism (the formulation was granted European patent protection ▇▇▇▇▇▇▇▇▇). JOTROL provides a unique solubilization product consisting of resveratrol, a mixture of polysorbate 80 and polysorbate 20 as well as at least one medium-chain triglyceride and tocopherol. The structure of JOTROL is micellar with a size of approximately 30 nm, like the structure of the naturally formed physiological mixed micelles containing water-insoluble compounds in its core, which is enclosed by ambiphilic molecules. The higher bioavailability, which is obtained by the product micellation, is based on the independence of this transport system from the limiting parameters in the formation of the physiological mixed micelle. It is important to appreciate the product micellar character as an “encapsulation and transport medium”. Resveratrol micellar formulation increases peak blood plasma levels at least 10-fold more than non-formulated resveratrol. Our preliminary data show that JOTROL is pharmacologically active in rodent brain. A pilot human exposure experiment showed similar results. Importantly, a reduction of body burden is also expected to result in fewer side effects. Further, JOTROL has been approved for clinical trials for MPSI, with a view toward using it in other neurological diseases such as Friedreich’s Ataxia and Alzheimer’s disease, demonstrating its potential utility to progress into clinical phases for a spectrum of neurological disorders.

Confidential 7

Center for Therapeutic Innovation, University of Miami ▇▇▇▇▇▇ School of Medicine

EXPERIMENTAL APPROACH

Goal: Evaluate Resveratrol and JOTROL Activity in ▇▇▇▇▇▇▇▇▇’▇ Disease (PD) Toxin Models

Objective 1: Validate the protective capacity of JOTROL in a unilateral intracranial MPTP model using motor behavioral testing.

The activity of unformulated resveratrol and JOTROL will be validated in an intracranial MPTP model of PD and sham-infused C57/BL6 mice, this approach has been directly modeled based upon work that is currently in phase II clinical trials for other drugs^71–74. In this milestone, we will work to validate the overall neuroprotective capacity of JOTROL on general health and motor behavior. Firstly, animals will be microinfused with either vehicle (sham-infused controls) or MPTP using stereotaxic surgery to deliver these insults to both the substantia nigra pars compacta (SN) and medial forebrain bundle (MFB) of the nigrostriatal pathway. Animals are expected to recover within 24 hours and wound clips removed 7-10 days post-surgery. Following surgery, animals will undergo a functional observation battery (FOB) which is a noninvasive systemic neurological examination to detect gross functional deficits following exposure to chemicals. Observations of the animals will begin with their general behavior in their home cage, followed by measuring the animal’s general locomotion in an open-field test. Behaviors will be ranked (present/absent, or on a scale) and include body posture, activity, coordination of movement, respiration rate, lacrimation, grimace, righting response, arousal, ease of removal, handling reactivity, body weight, urination/defecation, and presence of stereotypy or self-mutilation⁷⁵. For the open-field test, animals will be placed in a PVC apparatus during their dark phase, and will be allowed 5 minutes for exploration, and 5 minutes for testing. During testing, locomotion, occupancy in the outer/inner areas and rearing will be measured. Weight measurements will continue daily to continue monitoring the health of the animals (Fig. 1).

Once the general health of the animals has been established (no endpoints reached) we will begin assessing the animals’ functional ability in several different motor and cognitive behavioral tests including:

Open Field. Spontaneous activities of the mice will be examined in the open field for 15 minutes (5 min of habituation and 10 min for testing). Both horizontal (locomotion) and vertical activities (rearing) are monitored by an overhead high-definition video recorder secured to the ceiling and behavior will be assessed using Ethovision software (unbiased)^40,41,76. During testing, the total locomotion, occupancy in the outer/inner areas, wall climbs, and rearing will be measured, with those animals infused with a toxin most likely to display deficits in rearing, increased wall climbs and time in the outer area near the wall. Those treated with JOTROL are expected to display activities like those infused with vehicle (sham), with such dysfunctional motor behaviors abolished.

Confidential 8

Center for Therapeutic Innovation, University of Miami ▇▇▇▇▇▇ School of Medicine

Grip Strength. Animals are placed in the center of a wire mesh screen consisting of 12 mm squares of 1 mm diameter wire. The screen is rotated to an inverted position 40 cm above a darkened padded surface (so the animal cannot see the ground). The amount of time from the point the animal reaches the inverted position until the mouse falls off, or when the animal is removed because the criterion time of 180 seconds has been reached, will be recorded and the average of three trials is used for analysis (Fig. 2)⁷⁷. Animals infused with a toxin are expected to demonstrate reduced grip strength. We anticipate that JOTROL will improve the grip strength deficit that occurs in PD models.

 

Rotarod. Mice are placed on the rods at 4 rpm and then accelerated over 30 seconds from 4 to 40 rpm. The maximum velocity (rpm) and the latency to fall (min) is recorded. Animals are tested twice with approximately 30 minutes between each trial and the average is used (Fig. 3)⁷⁸. Animals infused with a toxin are predicted to display poor time and speed during testing, however successful treatment with JOTROL should eradicate any motor concerns.

L-DOPA-responsive Behavior. Each animal will be tested for response to L-DOPA by first injecting carbidopa (2 mg/kg, i.p.) 20 min before administering L-DOPA (20 mg/kg, i.p.), 3 weeks after surgery then every 3 weeks throughout the duration of the study. Rotarod activity will be conducted as described above, between 30 and 120 min after receiving the L-DOPA injection (well within the therapeutic window of L-DOPA⁸⁸). To assess locomotor activity and forelimb asymmetry, animals are placed in the open field apparatus for 10 min to reach baseline activity levels. Animals will then receive carbidopa (2 mg/kg, i.p.) 20 min before administering L-DOPA (20 mg/kg, i.p.) and then returned to the same apparatus for a further 120 min. L-DOPA is expected to temporarily restore motor function to near normal levels in toxin-infused mice, so no changes or any other improvements are expected with JOTROL treatment.

Confidential 9

Center for Therapeutic Innovation, University of Miami ▇▇▇▇▇▇ School of Medicine

Rotation-induced Behavior. Two weeks following surgery, animals will be injected with methamphetamine (5 mg/kg, i.p.; we hold necessary DEA licensure and currently have methamphetamine in house) and recorded in the same PVC apparatus as the open-field test. Mice will habituate to their environment for 10 min before contralateral and ipsilateral turns are recorded for 90 min (Fig. 4)^29,82. This test will be conducted no more than bi-weekly to reduce desensitization to the drug. We expect JOTROL treatment will reduce the number of rotations in response to methamphetamine (sham-infused animals are not expected to rotate).

 

It is important to note that all testing will be conducted during the wake cycle of mice (at night, during their dark phase) and experimenters will be blinded to treatment conditions.

High plasma concentrations may be required and therefore we will work to secure large quantities of JOTROL. This may therefore necessitate having it synthesized by a chemistry lab and if so then, overall quality must be high with a purity expected to be >99.5%.

Readouts from daily JOTROL treatment are expected to have a positive impact on behavioral assays by attenuating motor deficits and neurological dysfunction resulting from the unilateral infusion of MPTP. Resultant behavioral effects will provide fundamental insight into the underlying mechanisms that are involved in governing the key mechanisms involved in PD pathophysiology and provide crucial knowledge about which neuromolecular pathways are relevant.

Objective 2: Validate protective capacity of JOTROL on dopaminergic neurons in the SN and dopamine content in the striatum.

The neuroprotective power of JOTROL will be determined by assessing any altered circuitry patterns in the unilateral MPTP model of PD and control animals that were treated with vehicle or JOTROL. In this sub-milestone, animals will be evaluated for dopaminergic integrity along the nigrostriatal pathway and dopamine content in the striatum. This will be conducted as follows:

Protein Extraction and Western Blot Analysis of Dopaminergic and GABAergic Markers and Cell Populations in ex vivo Brain Tissue. Animals will be anesthetized and rapidly decapitated for rapid brain harvest. Brain dissections will be conducted on a sterile petri dish over ice to retrieve separate hemispheres of the midbrain (SN) and striatal tissue. Samples retrieved will be stored at -80°C until testing. Samples will be rinsed and lysed using Mammalian Protein Extraction Reagent (MPER) supplemented with Halt Protease Inhibitor cocktail (Thermo Scientific). The samples will be frozen for at least 6 hours and thawed to promote lysis, and the samples will also be sonicated. Samples will then be centrifuged for 10 minutes at 14,000 x g. The supernatant will be transferred to new tubes and Bicinchoninic Acid (BCA) assay (▇▇▇▇▇▇) will be conducted and measured using the EnVision plate reader (PerkinElmer) to quantify protein.

Confidential 10

Center for Therapeutic Innovation, University of Miami ▇▇▇▇▇▇ School of Medicine

For western blots, the Criterion Blotter Western Blot system will be used (Bio-Rad). 30 ug of total protein in Laemmli sample buffer will be boiled for 10 minutes at 95-100°C. The samples will be loaded into 10% gels (Bio-Rad) with electrophoresis set to 60-100V. The protein in the gel will be transferred to PVDF membranes by wet-transfer at 100V for 30 minutes. The membranes will be blocked in 5% milk for one hour at room temperature, probed with primary antibodies overnight at 4°C in 5% BSA and with secondary antibodies for 1 hour at room temperature in 5% BSA. The blots will be visualized by C-DiGit Blot Scanner (Li-Cor) and the images quantified using ImageJ. Primary antibodies for dopaminergic and GABAergic populations and markers will be used including anti-TH, anti-DAT, anti-NeuN, anti-parvalbumin, anti-somatostatin, anti-dopamine receptor 1, anti-dopamine receptor 2, and β-actin (control). Secondary antibodies for each primary will be used for visualizing these proteins (Fig. 6)⁴⁰.

HPLC Analysis. To assess dopamine and GABA content in the striatum, we will again assess the fresh tissue samples collected as listed above. Striatal tissue will be lysed in 0.5 M perchloric acid. The levels of dopamine and GABA will be measured using the Reversed-phase Ultimate 3000 HPLC system with ECD detector and a reversed-phase column and analysed under the control of Chromeleon™ 7.2 Chromatography Data system. The mobile phase is a mixture of 1.3% NaAc, 0.5% sodium 1-heptanesulfonate, 0.01% EDTA (adjusted to pH 4.0 with 100% acetic acid), 2% methanol (v/v), and 7% Acetonitrile (v/v). All solutions for HPLC analysis will be double filtered through a 0.2 µm membrane and degassed before use, and the flow rate will be set to 1 mL/minute.

SUMMARY

We present here an enabling plan for clinical trials to evaluate JOTROL for the treatment of ▇▇▇▇▇▇▇▇▇’▇ disease (PD). Resveratrol and JOTROL appear to be safe, and any positive outcomes will serve to enable PD clinical trials. Milestones presented here are accompanied by go-no-go criteria, and costs associated with additional milestones will be discontinued at any time should such criteria not be met.

Confidential 11

Center for Therapeutic Innovation, University of Miami ▇▇▇▇▇▇ School of Medicine

REFERENCES

(1)	▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇▇▇▇’▇ Disease: Mechanisms and Models. Neuron 2003, 39 (6), 889–909.
(2)	▇▇▇▇▇▇, A. D.; ▇▇▇▇▇▇▇, P.; ▇▇▇▇▇▇▇, J. Neurodegenerative Disease: Models, Mechanisms, and a New Hope. Dis Model Mech 2017, 10 (5), 499–502. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇.▇▇▇▇▇▇.
(3)	▇▇▇▇▇▇▇▇▇, J.; ▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇▇▇▇▇▇▇ of ▇▇▇▇▇▇▇▇▇’▇ Disease: Dopamine, Vesicles and Alpha-Synuclein. Nature reviews. Neuroscience 2002, 3 (12), 932–942. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇.
(4)	▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇, P.; ▇▇▇▇▇▇▇, P.; ▇▇▇▇, G. Behavioral Characterization of a Unilateral 6-OHDA-Lesion Model of ▇▇▇▇▇▇▇▇▇’▇ Disease in Mice. Behavioural brain research 2005, 162 (1), 1–10. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(5)	Treatment & Medication | American ▇▇▇▇▇▇▇▇▇ Disease Assoc. APDA.
(6)	▇▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇, M. S. Diagnosis and Treatment of ▇▇▇▇▇▇▇▇▇ Disease: A Review. JAMA 2020, 323 (6), 548–560. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇.▇▇▇▇.▇▇▇▇▇.
(7)	▇▇▇▇▇▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇▇, K.; ▇▇▇▇▇▇▇, B. B. A.; ▇▇▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, ▇. ▇. L-DOPA Causes Mitochondrial Dysfunction in Vitro: A Novel Mechanism of L-DOPA Toxicity Uncovered. Int J Biochem Cell Biol 2019, 117, 105624. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇▇▇.▇▇▇▇.▇▇▇▇▇▇.
(8)	▇▇▇▇, M.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, F.; ▇▇▇▇▇▇, ▇. The Design and Evaluation of an L-Dopa-Lazabemide Prodrug for the Treatment of ▇▇▇▇▇▇▇▇▇’▇ Disease. Molecules 2017, 22 (12). ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.
(9)	▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇▇▇ (L-Dopa). In StatPearls; StatPearls Publishing: Treasure Island (FL), 2020.
(10)	▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇, E. N.; ▇▇▇▇▇▇▇▇, E.; ▇▇▇▇▇▇▇, J. Mortality in Patients with ▇▇▇▇▇▇▇▇▇’▇ Disease. Acta Neurologica Scandinavica 1995, 92 (1), 55–58. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇-▇▇▇▇.▇▇▇▇.▇▇▇▇▇▇▇.▇.
(11)	▇▇▇, ▇. ▇.; ▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, P. Chapter Eleven - Hallmarks of Treatment Aspects: ▇▇▇▇▇▇▇▇▇’▇ Disease Throughout Centuries Including l-Dopa. In International Review of Neurobiology; ▇▇▇▇▇▇, ▇. ▇., ▇▇▇▇▇▇▇▇▇, ▇. ▇., ▇▇▇▇▇▇▇▇, M., Eds.; ▇▇▇▇▇▇▇▇▇’▇ Disease; Academic Press, 2017; Vol. 132, pp 295–343. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇.▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(12)	▇▇▇▇▇, ▇. ▇.; ▇▇▇▇-▇▇▇▇▇▇▇, P. M.; ▇▇▇▇▇▇, S.; ▇▇▇▇, S.; ▇▇▇▇▇▇▇▇▇, A.; ▇▇▇▇, ▇. ▇.; ▇▇▇▇, ▇.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, J.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, T.; ▇▇▇▇, N. W. A Common LRRK2 Mutation in Idiopathic ▇▇▇▇▇▇▇▇▇’▇ Disease. Lancet 2005, 365 (9457), 415–416. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇-▇▇▇▇(▇▇)▇▇▇▇▇-▇.
(13)	▇▇▇, ▇. ▇. ▇.; ▇▇▇▇▇▇▇▇, M. M. B. Epidemiology of ▇▇▇▇▇▇▇▇▇’▇ Disease. The Lancet. Neurology 2006, 5 (June), 525–535. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇-▇▇▇▇(▇▇)▇▇▇▇▇-▇.
(14)	▇▇▇, ▇.; ▇▇▇▇▇▇▇▇, D.; ▇▇▇▇▇▇▇▇, D.; ▇▇▇▇▇▇▇, E.; ▇▇▇▇▇, D. Role of DJ-1 in ▇▇▇▇▇▇▇▇▇’▇ Disease. Journal of molecular neuroscience: MN 2006, 29 (3), 215–225. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇:▇▇:▇:▇▇▇.
(15)	▇▇▇▇-▇▇▇▇, M.; ▇▇▇▇▇▇▇-▇▇▇▇▇, J.; ▇▇▇▇▇▇▇▇▇▇▇-▇▇▇▇, B. Environmental Pollutants as Risk Factors for Neurodegenerative Disorders: Alzheimer and ▇▇▇▇▇▇▇▇▇ Diseases. Frontiers in Cellular Neuroscience 2015, 9 (April), 1–22. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇.▇▇▇▇.▇▇▇▇▇.
(16)	▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, M. Role of Reactive Oxygen Species in the Neurotoxicity of Environmental Agents Implicated in ▇▇▇▇▇▇▇▇▇’▇ Disease. Free Radical Biology and Medicine 2008, 44 (11), 1873–1886. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(17)	▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, ▇. ▇. ▇▇▇▇▇▇▇▇▇’▇ Disease and Pesticides: A Toxicological Perspective. Trends in Pharmacological Sciences 2008, 29 (6), 322–329. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(18)	▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, ▇. ▇. Etiology and Pathogenesis of ▇▇▇▇▇▇▇▇▇’▇ Disease. Annual review of neuroscience 1999, 22, 123–144. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇▇.▇▇▇▇▇.▇▇.▇.▇▇▇.

Confidential 12

Center for Therapeutic Innovation, University of Miami ▇▇▇▇▇▇ School of Medicine

(19)	▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇, N. W.; ▇▇, ▇.; ▇▇▇, ▇.-▇.; ▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇▇▇, M.; ▇▇▇▇▇, T.; ▇▇▇▇▇▇▇, C.; ▇▇▇▇, ▇.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇, H.; ▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, X. Lateralized Basal Ganglia Vulnerability to Pesticide Exposure in Asymptomatic Agricultural Workers. Toxicol. Sci. 2017, 159 (1), 170–178. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇/▇▇▇▇▇▇.
(20)	▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, ▇.; ▇▇▇▇▇, M. A.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, ▇. ▇. Pesticide Exposure and Risk of ▇▇▇▇▇▇▇▇▇’▇ Disease: A Family-Based Case-Control Study. BMC Neurol 2008, 8, 6. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇-▇▇▇▇-▇-▇.
(21)	▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, R. F.; ▇▇▇▇▇▇, S. E.; ▇▇▇▇, D. Organochlorine Insecticides in Substantia Nigra in ▇▇▇▇▇▇▇▇▇’▇ Disease. J. Toxicol. Environ. Health Part A 2000, 59 (4), 229–234.
(22)	▇▇▇▇▇▇▇, ▇.; ▇▇▇▇, ▇. ▇.; ▇▇▇▇, J.; ▇▇▇▇▇▇▇, T.; ▇▇▇▇▇▇▇-▇▇▇▇▇, J. R. ▇▇▇▇▇▇▇▇▇’▇ Disease and Brain Levels of Organochlorine Pesticides. Annals of Neurology 1994, 36 (1), 100–103. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇.▇▇▇▇▇▇▇▇▇.
(23)	▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, M. A.; ▇▇▇▇▇▇▇, A. K. Acute and Reversible Parkinsonism Due to Organophosphate Pesticide Intoxication: Five Cases. Neurology 1999, 52 (7), 1467–1471.
(24)	▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇, R.; ▇▇▇▇▇▇-▇▇▇▇, K. Transient Severe Parkinsonism after Acute Organophosphate Poisoning. J Neurol Neurosurg Psychiatry 1999, 66 (2), 253–254.
(25)	▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, ▇.▇. Chronic Parkinsonism Secondary to Intravenous Injection of Meperidine Analogues.; 1979; Vol. 1, pp 249–254.
(26)	▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, F.; ▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, M.; ▇▇▇▇▇▇, C.; ▇▇▇▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, M.; ▇▇▇▇▇, A. R.; ▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇, M. B.; ▇▇▇▇, C.; ▇▇▇▇▇▇▇▇▇, B.; ▇▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, F.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, A.; ▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇, ▇. ▇. Rotenone, Paraquat, and ▇▇▇▇▇▇▇▇▇’▇ Disease. Environ Health Perspect 2011, 119 (6), 866–872. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇.▇▇▇▇▇▇▇.
(27)	▇▇▇▇▇▇▇, A. Classic Toxin-Induced Animal Models of ▇▇▇▇▇▇▇▇▇’▇ Disease: 6-OHDA and MPTP.Cell and Tissue Research 2004, 318 (1), 215–224. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇-▇▇▇-▇▇▇▇-▇.
(28)	▇▇▇▇▇▇▇, M.; ▇▇▇▇▇▇▇▇, P. Animal Models of ▇▇▇▇▇▇▇▇▇’▇ Disease: An Empirical Comparison with the Phenomenology of the Disease in Man. Journal of Neural Transmission 1996, 103 (8–9), 987–1041. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇▇▇▇▇.
(29)	▇▇▇▇, N. H.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, ▇. ▇. Altered Melatonin MT1 Receptor Expression in the Ventral Midbrain Following 6-Hydroxydopamine Lesions in the Rat Medial Forebrain Bundle. Brain Research 2016, 1652, 89–96. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇▇▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(30)	▇▇▇▇, ▇.; ▇▇▇▇▇▇, C. Neurotoxin-Based Models of ▇▇▇▇▇▇▇▇▇’▇ Disease. Neuroscience 2012, 211, 51–76. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(31)	▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇▇▇▇, S. A Tale on Animal Models of ▇▇▇▇▇▇▇▇▇’▇ Disease. Movement Disorders 2011, 26 (6), 993–1002. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇.▇▇▇▇▇.
(32)	▇▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇▇, M. Animal Models of ▇▇▇▇▇▇▇▇▇’▇ Disease. The FEBS journal 2012, 279 (7), 1156–1166. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇-▇▇▇▇.▇▇▇▇.▇▇▇▇▇.▇.
(33)	▇▇▇▇▇▇, ▇.; ▇▇▇, Z.; ▇▇▇▇▇, D.; ▇▇▇▇▇▇▇▇▇▇▇, M. G. Animal Models of ▇▇▇▇▇▇▇▇▇’▇ Disease: Limits and Relevance to Neuroprotection Studies. Movement Disorders 2013, 28 (1), 61–70. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇.▇▇▇▇▇.
(34)	▇▇▇▇, ▇. ▇. Experimental Models of ▇▇▇▇▇▇▇▇▇’▇ Disease. Nature reviews. Neuroscience 2001, 2(5), 325–334. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇▇▇.
(35)	▇▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇, A. M. Progress in ▇▇▇▇▇▇▇▇▇’▇ Disease-Where Do We Stand? Progress in Neurobiology 2008, 85 (4), 376–392. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇▇▇▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(36)	▇▇▇▇▇, ▇.; ▇▇▇▇▇, P.; ▇▇▇▇▇, B.; ▇▇▇▇▇, A.; ▇▇▇▇▇▇▇▇▇▇, C.; ▇▇▇▇, M. D. Pargyline and Deprenyl Prevent the Neurotoxicity of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) in Monkeys. European journal of pharmacology 1984, 106 (1), 209–210. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇-▇▇▇▇(▇▇)▇▇▇▇▇-▇.

Confidential 13

Center for Therapeutic Innovation, University of Miami ▇▇▇▇▇▇ School of Medicine

(37)	▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇, M.; ▇▇▇▇▇▇▇▇▇▇, P. Therapeutic Strategies in ▇▇▇▇▇▇▇▇▇’▇ Disease: What We Have Learned from Animal Models. Annals of the New York Academy of Sciences 2014, 1338, n/a-n/a. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇.▇▇▇▇▇.
(38)	Alam, M.; ▇▇▇▇▇▇▇, ▇. ▇. Rotenone Destroys Dopaminergic Neurons and Induces Parkinsonian Symptoms in Rats. Behavioural brain research 2002, 136 (1), 317–324.
(39)	▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, V.; ▇▇, H. M.; ▇▇▇▇▇▇, A. S.; ▇▇▇▇▇▇, R. E.; ▇▇▇▇▇▇▇▇▇▇, ▇. ▇. A Highly Reproducible Rotenone Model of ▇▇▇▇▇▇▇▇▇’▇ Disease. Neurobiology of Disease 2009, 34 (2), 279–290. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(40)	▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇, N. H.; ▇▇▇▇▇, ▇. ▇. Neuroprotection by Valproic Acid in an Intrastriatal Rotenone Model of ▇▇▇▇▇▇▇▇▇’▇ Disease. Neuroscience 2014, 267, 114–121. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(41)	▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇, N. H.; ▇▇▇▇▇, ▇. ▇. Bilateral Upregulation of α-Synuclein Expression in the Mouse Substantia Nigra by Intracranial Rotenone Treatment. Exp. Toxicol. Pathol. 2017, 69 (2), 109–114. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(42)	▇▇▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇, R.; ▇▇▇▇▇▇, ▇. ▇. The Rotenone Model of ▇▇▇▇▇▇▇▇▇’▇ Disease: Genes, Environment and Mitochondria. Parkinsonism & Related Disorders 2003, 9, 59–64. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇-▇▇▇▇(▇▇)▇▇▇▇▇-▇.
(43)	▇▇▇▇▇▇▇, S.; ▇▇▇▇▇, V.; ▇▇▇▇▇▇▇▇▇, P.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, H.; ▇▇▇▇▇, A. G.; ▇▇▇▇, C. S. Telmisartan Attenuates MPTP Induced Dopaminergic Degeneration and Motor Dysfunction through Regulation of A-Synuclein and Neurotrophic Factors (BDNF and GDNF) Expression in C57BL/6J Mice. Neuropharmacology 2013, 73, 98–110. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇▇▇▇▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(44)	▇▇▇▇, M.; ▇▇▇▇▇▇▇▇▇, S.; ▇▇▇▇▇▇▇-▇▇▇▇▇, V.; ▇▇▇▇▇▇▇, M.; ▇▇▇▇▇▇▇, M.; ▇▇▇▇▇▇▇▇▇▇▇, S. Alpha-Synuclein up-Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP. Journal of Neurochemistry 2000, 74 (2), 721–729. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇-▇▇▇▇.▇▇▇▇.▇▇▇▇▇▇.▇.
(45)	▇▇▇ ▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇, ▇.; ▇▇▇▇, N.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇, M. The Rotenone-Induced Rat Model of ▇▇▇▇▇▇▇▇▇’▇ Disease: Behavioral and Electrophysiological Findings. Behav. Brain Res. 2015, 279, 52–61. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(46)	▇▇▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, C. Mitochondrial Dysfunction in ▇▇▇▇▇▇▇▇▇’▇ Disease. Biochimica et biophysica acta 2010, 1802 (1), 29–44. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(47)	▇▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, J. Animal Models of ▇▇▇▇▇▇▇▇▇’▇ Disease.BioEssays 2002, 24 (4), 308–318. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇.▇▇▇▇▇.
(48)	▇▇▇▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇▇▇▇▇, ▇.; Jellinger, ▇.; ▇▇▇▇▇▇▇▇▇▇▇▇, F. Brain Dopamine and the Syndromes of ▇▇▇▇▇▇▇▇▇ and ▇▇▇▇▇▇▇▇▇▇ Clinical, Morphological and Neurochemical Correlations. Journal of the Neurological Sciences 1973, 20 (4), 415–455. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇-▇▇▇▇(▇▇)▇▇▇▇▇-▇.
(49)	▇▇▇▇▇▇▇▇, N.; ▇▇▇▇▇▇, M.; ▇▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇▇▇ in ▇▇▇▇▇▇▇▇▇’▇ Disease: Current Status and Future Developments. Curr Neuropharmacol 2018, 16 (8), 1239–1252. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.
(50)	▇▇▇, S.-P. K. and ▇. The Pharmacokinetics and Pharmacodynamics of Levodopa in the Treatment of Parkinsons Disease ▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇/▇▇▇▇▇/▇▇▇▇▇▇▇ (accessed 2019 -04 -23).
(51)	▇▇▇▇▇▇▇, M. E.; ▇▇▇▇, ▇. ▇.; ▇▇▇, ▇. ▇. Motor Complications of Dopaminergic Medications in ▇▇▇▇▇▇▇▇▇’▇ Disease. Semin Neurol 2017, 37 (2), 147–157. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇-▇▇▇▇-▇▇▇▇▇▇▇.
(52)	▇▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, W.; ▇▇▇▇▇▇, D. Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features. Movement Disorders 2018, 33 (6), 909–919. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇.▇▇▇▇▇.

Confidential 14

Center for Therapeutic Innovation, University of Miami ▇▇▇▇▇▇ School of Medicine

(53)	▇▇▇▇, T. N.; Vo, T. N. N.; ▇▇▇▇, K.; ▇▇▇▇▇▇, ▇. ▇. Levodopa-Induced Dyskinesia: Clinical Features, Incidence, and Risk Factors. J Neural Transm 2018, 125 (8), 1109–1117. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇-▇▇▇-▇▇▇▇-▇.
(54)	▇▇▇▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇, ▇.; ▇▇▇, ▇. ▇. Update in Therapeutic Strategies for ▇▇▇▇▇▇▇▇▇’▇ Disease: Current Opinion in Neurology 2018, 1. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.
(55)	▇▇▇▇▇▇▇▇▇, F. N.; ▇▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇▇▇▇’▇ Disease: Biomarkers, Treatment, and Risk Factors. Front. Neurosci. 2018, 12. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇.▇▇▇▇.▇▇▇▇▇.
(56)	▇▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇, V.; ▇▇▇▇▇▇▇, M. Postural Disorders and Antiparkinsonian Treatments in ▇▇▇▇▇▇▇▇▇ Disease: An Exploratory Case-Control Study. Clinical Neuropharmacology 2018, 41 (4), 123–128. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.
(57)	▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇▇▇▇▇▇▇, R.; ▇▇▇, ▇.-▇.; ▇▇▇▇▇▇, B.; ▇▇▇, R. M. A. de; ▇▇▇▇▇, ▇.; ▇▇▇▇▇▇, M.; ▇▇▇▇▇▇▇, C. International ▇▇▇▇▇▇▇▇▇ and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of ▇▇▇▇▇▇▇▇▇’▇ Disease. Movement Disorders 2018, 33 (8), 1248–1266. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇.▇▇▇▇▇.
(58)	▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, ▇. ▇. ▇▇▇▇▇▇▇▇▇’▇ Disease. Medical Clinics of North America 2019, 103 (2), 337–350. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(59)	▇▇▇▇, ▇.; ▇▇▇▇▇, R.; ▇▇▇▇▇▇▇, N. ul ▇. ▇▇▇▇▇▇▇▇▇’▇ Disease: Mechanisms, Translational Models and Management Strategies. Life Sciences 2019, 226, 77–90. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(60)	▇▇▇▇▇▇▇▇, Q. D.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇▇, A. T.; ▇▇▇▇▇, E.; ▇▇▇▇▇▇▇▇▇▇, ▇. ▇.; Kohl, ▇.; ▇▇▇▇▇▇▇, C.; ▇▇▇▇, A. L.; ▇▇▇▇▇▇▇▇, J. R. Deep Brain Stimulation: Connectivity Profile for Bradykinesia Alleviation. Annals of Neurology 0 (ja). ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇.▇▇▇▇▇.
(61)	▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇, A. Chapter Thirty-Three - Nonmotor Fluctuations in ▇▇▇▇▇▇▇▇▇’▇ Disease. In International Review of Neurobiology; ▇▇▇▇▇▇▇▇▇, ▇. ▇., ▇▇▇▇▇▇, N., Eds.; Nonmotor ▇▇▇▇▇▇▇▇▇’▇: The Hidden Face; Academic Press, 2017; Vol. 134, pp 947–971. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇.▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(62)	▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇, C.; ▇▇▇▇▇, K.; ▇▇▇▇▇, P.; ▇▇▇▇▇▇▇, C.; ▇▇▇▇▇▇▇, U.; ▇▇▇▇▇▇, A. Nonmotor Fluctuations: Phenotypes, Pathophysiology, Management, and Open Issues. J Neural Transm 2017, 124 (8), 1029–1036. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇-▇▇▇-▇▇▇▇-▇.
(63)	▇▇▇▇, ▇. ▇. Treatment of Psychotic Symptoms in Patients with ▇▇▇▇▇▇▇▇▇ Disease. Ment Health Clin 2018, 7 (6), 262–270. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(64)	▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, S.; ▇▇▇ ▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, R.; ▇▇▇▇▇, P. S. A Randomized, Double-Blind, Placebo-Controlled Trial of Resveratrol for Alzheimer Disease. Neurology 2015, 85 (16), 1383–1391. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.
(65)	▇▇▇▇▇▇▇▇▇▇▇, I. M.; ▇▇▇▇▇▇, M.; ▇▇▇▇▇, Z.; ▇▇▇▇▇▇▇▇, T. N.; ▇▇▇▇▇▇▇▇▇, ▇. ▇. Pharmacokinetics, Oral Bioavailability, and Metabolic Profile of Resveratrol and Its Dimethylether Analog, Pterostilbene, in Rats. Cancer Chemother Pharmacol 2011, 68 (3), 593–601. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇-▇▇▇-▇▇▇▇-▇.
(66)	▇▇▇, ▇. ▇.; ▇▇▇, G.; ▇▇▇▇▇▇▇▇, R. E.; ▇▇▇, ▇. ▇.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇-▇▇▇▇▇▇▇▇▇, B.; ▇▇▇▇▇, B.; ▇▇▇▇▇▇▇▇▇▇▇▇, M.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, G.; ▇▇▇▇▇▇▇▇▇▇, S. E. M.; ▇▇▇▇▇▇▇, J. P.; ▇▇▇▇▇▇▇▇, C.; ▇▇▇, ▇.-▇. ▇.; ▇▇▇▇▇▇▇▇▇▇, A.; ▇▇▇▇▇-▇▇▇▇▇, ▇. ▇.; ▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, L. A.; ▇▇▇▇▇▇▇▇▇, M. B. An Open-Label Trial in Friedreich Ataxia Suggests Clinical Benefit with High-Dose Resveratrol, without Effect on Frataxin Levels. J Neurol 2015, 262 (5), 1344–1353. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇-▇▇▇-▇▇▇▇-▇.
(67)	▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, G. E. S.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, A. M.; ▇▇▇▇▇, V. A.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, M.; ▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, D. E. Phase I Dose Escalation Pharmacokinetic Study in Healthy Volunteers of Resveratrol, a Potential Cancer Chemopreventive Agent. Cancer Epidemiol Biomarkers Prev 2007, 16 (6), 1246–1252. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇-▇▇▇▇.▇▇▇-▇▇-▇▇▇▇.

Confidential 15

Center for Therapeutic Innovation, University of Miami ▇▇▇▇▇▇ School of Medicine

(68)	▇▇▇▇▇, T.; ▇▇▇▇▇, F.; ▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, U. K. High Absorption but Very Low Bioavailability of Oral Resveratrol in Humans. Drug Metab Dispos 2004, 32 (12), 1377–1382. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇.▇▇▇.▇▇▇▇▇▇.
(69)	Su, D.; ▇▇▇▇▇, Y.; ▇▇▇, M.; ▇▇▇, D.; ▇▇▇, ▇.; ▇▇▇▇▇, ▇.; ▇▇▇▇, ▇.; ▇▇▇▇, T.; ▇▇▇, Q. Comparision of ▇▇▇▇▇▇ and Resveratrol in Antioxidation and Antiproliferation Activities In Vitro. PLOS ONE 2013, 8 (1), e54505. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇▇.▇▇▇▇.▇▇▇▇▇▇▇.
(70)	▇▇▇▇▇▇▇, ▇.; ▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, F.; ▇▇▇▇▇▇▇▇-▇▇▇▇▇▇▇, K.; ▇▇▇▇▇, U. ▇▇ ▇.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, A. L.; ▇▇▇▇▇, G.; ▇▇▇▇▇, F.; ▇▇▇▇▇▇▇▇▇, R. Mucopolysaccharidosis Type I. Diagnostics (Basel) 2020, 10 (3). ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.
(71)	El-Shamarka, M. E. A.; ▇▇▇▇▇▇, M. R.; ▇▇▇▇▇▇▇, B. A. S. The Protective Effect of Inosine against Rotenone-Induced ▇▇▇▇▇▇▇▇▇’▇ Disease in Mice; Role of Oxido-Nitrosative Stress, ERK Phosphorylation, and A2AR Expression. ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇▇ Arch Pharmacol 2020, 393 (6), 1041–1053. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇-▇▇▇-▇▇▇▇▇-▇.
(72)	▇▇▇▇▇, ▇.; ▇▇▇▇, R.; ▇▇▇▇▇▇, N.; ▇▇▇▇, S.; ▇▇▇▇▇▇, T.; ▇▇▇▇, H.; ▇▇▇▇▇▇▇▇▇, N.; ▇▇▇▇▇, M.; ▇▇▇▇▇▇, M. One Year Safety and Efficacy of Inosine to Increase the Serum Urate Level for Patients with ▇▇▇▇▇▇▇▇▇’▇ Disease in Japan. Journal of the Neurological Sciences 2017, 383, 75–78. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(73)	▇▇▇▇▇▇▇▇▇ Study Group SURE-PD Investigators; ▇▇▇▇▇▇▇▇▇▇▇▇▇, M. A.; ▇▇▇▇▇▇▇▇, A.; ▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇▇, M. E.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, D.; ▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇, I.; Tennis, M. K.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, M.; ▇▇▇▇, ▇.; ▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇, R.; ▇▇▇▇▇▇▇▇▇▇▇, E.; ▇▇▇▇▇▇▇, M.; ▇▇▇▇▇▇▇▇, R.; ▇▇▇▇▇▇▇▇, D.; ▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, ▇.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, M.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, J.; ▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, C.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, D.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇, P.; ▇▇▇▇▇-▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, ▇.-▇.; ▇▇▇▇▇, ▇.; ▇▇▇▇▇, M. A.; ▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇, L.; ▇▇▇▇▇▇▇▇▇ ▇▇ ▇▇▇▇▇▇▇▇, J.; ▇▇▇▇▇▇▇, S.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇, ▇.; ▇▇▇, J.; ▇▇▇▇, M.; Hope-▇▇▇▇▇▇, C.; ▇▇▇▇▇▇▇, L.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, R.; ▇▇▇▇, C.; ▇▇▇▇, T.; ▇▇▇▇▇▇, A. F. D.; ▇▇▇▇▇▇▇▇▇▇▇▇▇▇, R.; ▇▇▇▇▇▇, S.; ▇▇▇▇▇▇, C.; ▇▇▇▇▇, J.; ▇▇▇▇▇, ▇. ▇▇▇▇▇▇▇ to Increase ▇▇▇▇▇ and Cerebrospinal Fluid Urate in ▇▇▇▇▇▇▇▇▇ Disease: A Randomized Clinical Trial. JAMA Neurol 2014, 71 (2), 141–150. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇▇▇▇▇.▇▇▇▇.▇▇▇▇.
(74)	▇▇▇▇▇▇▇▇▇▇▇▇▇, M. A.; ▇▇▇▇▇▇▇▇, A.; ▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇▇, M. E.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, D.; ▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇, I.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, M.; ▇▇▇▇, ▇.; ▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇, R.; ▇▇▇▇▇▇▇▇▇▇▇, E.; ▇▇▇▇▇▇▇, M.; ▇▇▇▇▇▇▇▇, R.; ▇▇▇▇▇▇▇▇, D.; ▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, L.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, M.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, ▇.; ▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, C.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, D.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇, P.; ▇▇▇▇▇-▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, ▇.-▇.; ▇▇▇▇▇, ▇.; ▇▇▇▇▇, M. A.; ▇▇▇▇▇▇▇, J.; ▇▇▇▇▇▇, L.; ▇▇▇▇▇▇▇▇, ▇. ▇. de; ▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇, ▇.; ▇▇▇, J.; ▇▇▇▇, M.; ▇▇▇▇-▇▇▇▇▇▇, C.; ▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, R.; ▇▇▇▇, C.; ▇▇▇▇, ▇.; ▇▇▇▇▇▇, A. F. D.; ▇▇▇▇▇▇▇▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇, S.; ▇▇▇▇▇▇, ▇.; ▇▇▇▇▇, ▇.; ▇▇▇▇▇, ▇. ▇▇▇▇▇▇▇ to Increase Serum and Cerebrospinal Fluid Urate in ▇▇▇▇▇▇▇▇▇ Disease: A Randomized Clinical Trial. JAMA Neurol 2014, 71 (2), 141–150. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇▇▇▇▇.▇▇▇▇.▇▇▇▇.
(75)	▇▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇, ▇. ▇. The ▇▇▇▇▇ Test and Functional Observational Battery (FOB) for Assessing the Effects of Compounds on Behavior, Physiology, and Safety Pharmacology in Rodents. Current Protocols in Pharmacology 2018, 83 (1), e43. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇.▇▇.
(76)	▇▇▇▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, M. C. Use of the Open Field Maze to Measure Locomotor and Anxiety-like Behavior in Mice. J Vis Exp 2015, No. 96. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇.
(77)	▇▇▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇, S.; ▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇, M.; ▇▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇, Y.; ▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇, S.; Takeda, M.; ▇▇▇▇▇, R.; ▇▇▇▇▇▇, Y.; ▇▇▇▇, N.; ▇▇▇▇▇▇, Y.; ▇▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇, S.; ▇▇▇▇▇▇, H. Modified Forelimb Grip Strength Test Detects Aging-Associated Physiological Decline in Skeletal Muscle Function in Male Mice. Scientific Reports 2017, 7 (1), 42323. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇▇▇▇.

Confidential 16

Center for Therapeutic Innovation, University of Miami ▇▇▇▇▇▇ School of Medicine

(78)	▇▇▇▇▇▇, ▇. ▇. ▇. Measuring Motor Coordination in Mice. J Vis Exp 2013, No. 75. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇.
(79)	▇▇▇▇▇▇▇▇, T.; ▇▇▇▇▇▇▇▇▇, J.; ▇▇▇▇▇▇▇▇▇▇▇, N.; ▇▇▇▇▇, B.; ▇▇▇▇▇▇▇▇▇, P.; ▇▇▇▇▇▇▇▇▇▇▇, ▇. ▇. Antiparkinsonian Effects of Aqueous Methanolic Extract of Hyoscyamus Niger Seeds Result From Its Monoamine Oxidase Inhibitory and Hydroxyl Radical Scavenging Potency. Neurochem Res 2011, 36 (1), 177–186. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇-▇▇▇-▇▇▇▇-▇.
(80)	▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, ▇. ▇. Behavioral Phenotyping of Mouse Models of ▇▇▇▇▇▇▇▇▇’▇ Disease. Behav Brain Res 2010, 211 (1), 1–10. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(81)	Duty, S.; ▇▇▇▇▇▇, P. Animal Models of ▇▇▇▇▇▇▇▇▇’▇ Disease: A Source of Novel Treatments and Clues to the Cause of the Disease. Br J Pharmacol 2011, 164 (4), 1357–1391. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇-▇▇▇▇.▇▇▇▇.▇▇▇▇▇.▇.
(82)	▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇, N. H.; ▇▇▇▇▇, ▇. ▇. Chronic Low-Dose Melatonin Treatment Maintains Nigrostriatal Integrity in an Intrastriatal Rotenone Model of ▇▇▇▇▇▇▇▇▇’▇ Disease. Brain Res. 2016, 1633, 115–125. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇▇▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(83)	▇▇▇▇▇, G.; ▇▇▇▇▇▇, V.; ▇▇▇▇▇▇▇▇▇, D.; ▇▇▇▇▇▇, M. M. de; ▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇, M. Impaired Spatial Learning Strategies and Novel Object Recognition in Mice Haploinsufficient for the Dual Specificity Tyrosine-Regulated Kinase-1A (Dyrk1A). PLOS ONE 2008, 3 (7), e2575. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇▇.▇▇▇▇.▇▇▇▇▇▇▇.
(84)	▇▇▇▇▇▇, N.; ▇▇▇▇▇▇-▇▇▇▇▇, A.; ▇▇▇▇▇▇, G.; ▇▇▇▇▇▇▇▇▇, R. Understanding Cognitive Deficits in ▇▇▇▇▇▇▇▇▇’▇ Disease: Lessons from Preclinical Animal Models. Learn Mem 2013, 20 (10), 592–600. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇.▇▇▇▇▇▇.▇▇▇.
(85)	▇▇▇▇▇, ▇. ▇. ▇▇▇▇▇▇ Maze Procedure for Spatial Learning and Memory in Mice. Bio ▇▇▇▇▇▇ ▇▇▇▇, 8 (5). ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇▇/▇▇▇▇▇▇▇▇▇.▇▇▇▇.
(86)	▇▇▇▇▇▇, ▇. ▇. Memory Deficits Associated with Senescence: A Neurophysiological and Behavioral Study in the Rat. J Comp Physiol Psychol 1979, 93 (1), 74–104. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇▇▇.
(87)	▇▇▇▇▇▇, ▇.; ▇▇▇▇▇, K.; ▇▇▇▇▇▇▇▇, T. Elevated Plus Maze for Mice. J Vis Exp 2008, No. 22. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇.
(88)	▇▇▇▇▇▇▇▇▇▇, R. E.; ▇▇▇▇▇, T.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇, ▇.; ▇▇▇▇▇, P. C. Age-Related Decline in Striatal Dopamine Content and Motor Performance Occurs in the Absence of Nigral Cell Loss in a Genetic Mouse Model of ▇▇▇▇▇▇▇▇▇’▇ Disease. European Journal of Neuroscience 2006, 24 (9), 2622–2630. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇-▇▇▇▇.▇▇▇▇.▇▇▇▇▇.▇.
(89)	▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇, R. In Vivo Electrophysiological Measurements on Mouse Sciatic Nerves. J Vis Exp 2014, No. 86. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇.
(90)	▇▇▇▇▇, ▇.; ▇▇▇▇, ▇.; ▇▇▇, F.; ▇▇▇▇, ▇.; ▇▇▇, Z.; ▇▇▇▇▇▇, M. A.; ▇▇▇▇▇, ▇. ▇. Kcnj6(GIRK2) Trisomy Is Not Sufficient for Conferring the Susceptibility to Infantile Spasms Seen in the Ts65Dn Mouse Model of down Syndrome. Epilepsy Research 2018, 145, 82–88. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇▇▇▇▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(91)	▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇, W. X.; ▇▇▇▇, A. D.; ▇▇▇▇▇▇, ▇.; ▇▇▇▇▇, B. E.; ▇▇▇, Y.; ▇▇▇▇▇▇▇▇, J.; ▇▇▇▇▇▇▇, H.; ▇▇▇▇▇▇▇, L.; ▇▇▇▇▇▇▇, ▇.; ▇▇▇▇, ▇.; ▇▇▇▇, ▇.-▇.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇, ▇. ▇. The γ-Protocadherins Regulate the Survival of GABAergic Interneurons during Developmental Cell Death. ▇. ▇▇▇▇▇▇▇▇. 2020, 40 (45), 8652–8668. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇▇▇▇.▇▇▇▇-▇▇.▇▇▇▇.
(92)	▇▇▇▇▇▇, B.; ▇▇, N.; ▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇▇▇-induced Dyskinesia in ▇▇▇▇▇▇▇▇▇’▇ Disease: Clinical Features, Pathogenesis, Prevention and Treatment. Postgrad Med J 2007, 83 (980), 384–388. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇.▇▇▇▇.▇▇▇▇▇▇.
(93)	▇▇▇▇▇▇, G.; ▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇, P.; ▇▇, Q.; ▇▇▇▇▇, M.; ▇▇▇▇▇▇▇▇▇▇▇, R.; ▇▇▇▇, R.; ▇▇▇▇▇▇, E.; ▇▇▇▇▇▇, M.; ▇▇▇▇▇▇▇▇, ▇. ▇. L-Dopa-Induced Dyskinesia: Beyond an Excessive Dopamine Tone in the Striatum. Scientific Reports 2014, 4 (1), 3730. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇▇▇▇.

Confidential 17

Center for Therapeutic Innovation, University of Miami ▇▇▇▇▇▇ School of Medicine

(94)	▇▇▇▇, Q.; ▇▇▇▇▇, S.; ▇▇▇, Y.; ▇▇▇▇, W.; ▇▇▇▇, J.; ▇▇▇▇▇, C.; ▇▇▇▇, X.; ▇▇, Y.; ▇▇▇, X.; ▇▇, ▇. The Rodent Models of Dyskinesia and Their Behavioral Assessment. Front. Neurol. 2019, 10. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇.▇▇▇▇.▇▇▇▇▇.
(95)	▇▇▇▇▇, M. A.; ▇▇▇▇▇▇▇▇, M. Ratings of L-DOPA-Induced Dyskinesia in the Unilateral 6-OHDA Lesion Model of ▇▇▇▇▇▇▇▇▇’▇ Disease in Rats and Mice. Current Protocols in Neuroscience 2007, 41 (1), 9.25.1-9.25.23. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇▇▇▇▇.▇▇▇▇▇▇▇▇▇.
(96)	▇▇▇▇▇, ▇. ▇.; ▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇▇, A. L-DOPA-Induced Dyskinesia in the Rat Is Associated with Striatal Overexpression of Prodynorphin- and Glutamic Acid Decarboxylase MRNA. European Journal of Neuroscience 1998, 10 (8), 2694–2706. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇- 9568.1998.00285.x.
(97)	▇▇▇▇▇▇▇▇▇, M.; ▇▇▇▇▇▇▇▇▇▇, A.; ▇▇▇▇▇, M. A. Striatal FosB Expression Is Causally Linked with L- DOPA-Induced Abnormal Involuntary Movements and the Associated Upregulation of Striatal Prodynorphin MRNA in a Rat Model of ▇▇▇▇▇▇▇▇▇’▇ Disease. Neurobiology of Disease 1999, 6 (6), 461–474. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇.▇▇▇▇.▇▇▇▇.
(98)	▇▇▇▇▇▇▇▇, M.; ▇▇▇▇▇▇▇, B.; ▇▇▇▇▇▇▇▇, H.; ▇▇▇▇▇, M. A. A Model of L-DOPA-Induced Dyskinesia in 6-Hydroxydopamine Lesioned Mice: Relation to Motor and Cellular Parameters of Nigrostriatal Function. Neurobiology of Disease 2004, 16 (1), 110–123. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(99)	▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇, M.; ▇▇▇▇▇▇▇, E.; ▇▇▇▇▇▇▇, ▇. The Metabotropic Glutamate Receptor Antagonist 2-Methyl-6-(Phenylethynyl) Pyridine Decreases Striatal VGlut2 Expression in Association with an Attenuation of L-Dopa-Induced Dyskinesias. Synapse 2011, 65 (10), 1080–1086. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇.▇▇▇▇▇.
(100)	▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇, E. L. Comparison of Rating Scales Used to Evaluate L- DOPA-Induced Dyskinesia in the 6-OHDA Lesioned Rat. Neurobiology of Disease 2013, 50, 142–150. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(101)	▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇, C. The Effects of the β-Lactam Antibiotic, Ceftriaxone, on Forepaw Stepping and l-DOPA-Induced Dyskinesia in a Rodent Model of ▇▇▇▇▇▇▇▇▇’▇ Disease. Psychopharmacology 2014, 231 (12), 2405–2415. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇-▇▇▇-▇▇▇▇-▇.
(102)	▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, T.; ▇▇▇▇▇, V.; ▇▇▇▇▇▇▇▇▇, A. Anti-Dyskinetic Effects of Cannabinoids in a Rat Model of ▇▇▇▇▇▇▇▇▇’▇ Disease: Role of CB1 and TRPV1 Receptors. Exp Neurol 2007, 208 (1), 110–119. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇▇▇▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(103)	Sancesario, G.; ▇▇▇▇▇▇▇, L. A.; D’Angelo, V.; ▇▇▇▇▇▇▇▇, V.; ▇▇▇▇▇▇▇▇▇▇, D.; ▇▇▇▇, F.; ▇▇▇▇▇▇▇▇▇, A.; ▇▇▇▇▇, R.; ▇▇▇▇▇▇▇▇▇, F.; ▇▇▇▇▇▇▇▇, G.; ▇▇▇▇▇▇, M. Levodopa-Induced Dyskinesias Are Associated with Transient down-Regulation of CAMP and CGMP in the Caudate-Putamen of Hemiparkinsonian Rats: Reduced Synthesis or Increased Catabolism? Neurochemistry International 2014, 79, 44–56. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇.▇▇▇▇▇▇.▇▇▇▇.▇▇.▇▇▇.
(104)	▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇▇, ▇. ▇. If You Assume, You Can Make an Ass out of u and Me’: A Decade of the Disector for Stereological Counting of Particles in 3D Space. ▇. ▇▇▇▇. 1996, 188 ( Pt 1), 1–15.
(105)	▇▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇▇▇▇, D.; ▇▇▇▇▇▇▇▇▇▇, A.; ▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, A.; ▇▇▇▇▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇, ▇. ▇. The Gut-Brain Axis in Neurodegenerative Diseases and Relevance of the Canine Model: A Review. Front Aging Neurosci 2019, 11. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇.▇▇▇▇.▇▇▇▇▇.
(106)	▇’▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇, S.; ▇▇▇▇▇▇, J. R.; ▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇,
	▇. ▇. Genetic Mapping of Canine Multiple System Degeneration and Ectodermal Dysplasia Loci. Journal of Heredity 2005, 96 (7), 727–734. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇/▇▇▇▇▇▇.
(107)	Vets Focus On Neurological Disorders In Dogs, Humans ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇/▇▇▇▇▇▇▇▇/▇▇▇▇/▇▇/▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ (accessed 2021 -01 -17).
(108)	▇▇▇▇▇▇▇▇, P.; ▇▇▇▇▇▇, S.; ▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇▇▇▇ in ▇▇▇▇▇▇▇▇▇’▇ Disease: Methods of Assessment and Clinical Relevance. J Neurol 2000, 247 (2), 88–96. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇▇▇▇▇.

Confidential 18

Center for Therapeutic Innovation, University of Miami ▇▇▇▇▇▇ School of Medicine

(109)	▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇-▇▇▇▇▇▇, M. Human Olfactory Discrimination after Unilateral Frontal or Temporal Lobectomy. Brain 1991, 114 ( Pt 1A), 71–84.
(110)	▇▇▇▇▇▇, ▇.; ▇▇▇▇▇▇▇▇, P. Assessing Olfaction in the Italian Population: Methodology and Clinical Application. Ital J Neurol Sci 1999, 20 (5), 287–296. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇▇▇▇▇▇▇▇.
(111)	▇▇▇▇▇, I. Olfactory Bedside Test: A Simple Approach to Identify Temporo-Orbitofrontal Dysfunction. Arch Neurol 1997, 54 (2), 162. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇▇▇.▇▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇.
(112)	▇▇▇▇▇▇▇▇▇▇▇, M.; ▇▇▇▇▇▇▇, ▇. ▇. Odor Recognition Memory in Humans: Role of Right Temporal and Orbitofrontal Regions. Brain and Cognition 1993, 22 (2), 182–198. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇.▇▇▇▇.▇▇▇▇.
(113)	▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇, ▇. ▇. RECOGNITION MEMORY FOR ODORS. Chem Senses 1975, 1 (3), 331–337. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇/▇.▇.▇▇▇.
(114)	▇▇▇▇▇▇▇▇▇▇, ▇. ▇. ▇.; ▇▇▇▇▇, ▇. ▇. Cognition and Olfaction: A Review. Psychological Bulletin 1989, 105 (3), 352–360. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇-▇▇▇▇.▇▇▇.▇.▇▇▇.
(115)	▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇▇, M. A. Effects of Encoding Strategy on Long-Term Memory for Odours. The Quarterly Journal of Experimental Psychology Section A 1986, 38 (4), 753–765. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.
(116)	▇▇▇▇▇, ▇.; ▇▇▇▇▇, V.; ▇▇▇▇▇▇▇, F.; ▇▇▇▇▇▇▇▇▇, ▇. ▇.; ▇▇▇▇▇▇▇, M.; ▇▇▇▇▇▇▇▇▇▇▇▇, A. Valproic Acid Is Neuroprotective in the Rotenone Rat Model of ▇▇▇▇▇▇▇▇▇’▇ Disease: Involvement of Alpha- Synuclein. Neurotoxicity research 2010, 17 (2), 130–141. ▇▇▇▇▇://▇▇▇.▇▇▇/▇▇.▇▇▇▇/▇▇▇▇▇▇-▇▇▇-▇▇▇▇-▇.

Confidential 19

EXHIBIT B

Budget

BUDGET

PERSONNEL		7/1/2022 - 6/30/2023		Effort				Total				Total
NAME		ROLE IN PROJECT		%				Salary				FB				TOTALS
▇▇▇▇▇ ▇▇▇▇▇▇▇▇		PD/PI			3	%			4,900				1,343				6,243
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇		Post Doc			20	%			12,645				3,465				16,110
									Total personnel								22,353
EQUIPMENT
Digital mouse sterotaxic fame																	8,495
Equipment total																	8,495
SUPPLIES (Technical)																	8,237
Supplies subtotal																	8,237
OTHER EXPENSES
Gas anesthesia mask/earbars/infusion pump																	3,365
Animal related expenses																	7,966
Other Expenses subtotal																	11,331
TOTAL DIRECT COSTS																$	50,416
TOTAL INDIRECT COSTS (53.5%)																$	22,428
GRAND TOTAL																$	72,844

1